At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
Blinatumomab (MT103)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label, Multicenter Phase II Study to Investigate the Efficacy, Safety, and Tolerability of the Bispecific T-cell Engager (BiTE®) MT103 in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia
In Brief
A Phase 2 clinical trial evaluating Blinatumomab (MT103) for Acute Lymphoblastic Leukemia. Completed, enrolled 21 participants across 6 sites.
Detailed Summary
The purpose of this study is to determine whether the bispecific T-cell engager (BiTE®) Blinatumomab (MT103) is effective in the treatment of ALL patients with minimal residual disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Lymphoblastic Leukemia
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2007
Enrollment StartJan 2008
Primary CompletionSep 2009
Study CompletionNov 2014
TodayJul 2026
First PostedNov 20, 2007
Enrollment StartJan 1, 2008
Primary CompletionSep 1, 2009
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 18.6 years ago
Interventions
Blinatumomab (MT103)biological
Administered by continuous intravenous (CIV) over 4 weeks per cycle